Intended for healthcare professionals


India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracen

BMJ 2013; 347 doi: (Published 05 July 2013) Cite this as: BMJ 2013;347:f4366

This article has a correction. Please see:

  1. Soumyadeep Bhaumik
  1. 1Kolkata

India’s ministry of health and family welfare has banned the popular diabetes drug pioglitazone, the painkiller metamizole, and the psychiatric combination flupentixol with melitracen with immediate effect, because it said that their use was “likely to involve risk to human beings.”

The move is a response to a report from a parliamentary standing committee in April that criticised the ministry for failing to withdraw several drugs …

View Full Text

Log in

Log in through your institution


* For online subscription